Globus Medical (GMED) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and Globus Medical published the results on November 5, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison. Globus Medical reports EPS two ways: GAAP, under the accounting rules every US filer follows, and non-GAAP diluted, which leaves out items the company considers outside its operating results. The release reconciles the two, and when they diverge, the reconciliation says why.

• Globus Medical has two operating segments, Musculoskeletal Solutions and Enabling Technologies, which it aggregates into one reportable segment. The split shown is its net sales by product category.
• Globus acquired Nevro, a spinal cord stimulation company, on April 3, 2025. Nevro products contributed $73.7 million of Q3 2026 net sales, against $99.3 million a year earlier; Globus reports base business sales of $690.0 million excluding Nevro.
• Globus cut its full-year 2026 revenue guidance in this release, to $3.09 billion from $3.18 billion to $3.22 billion, while keeping its non-GAAP EPS range.

Source: Globus Medical Q3 2026 results, November 5, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How Globus Medical splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• Globus Medical's Musculoskeletal Solutions revenue was $729 million in Q3 2026, down 2% from $741 million in Q3 2025, 95% of total revenue.
• Globus Medical's Enabling Technologies revenue was $34.9 million in Q3 2026, up 25% from $28.0 million in Q3 2025, 5% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

In its Q3 2026 release, Globus Medical said:

“The Company is updating its guidance for full-year 2026 revenue to $3.09 billion from the previous range of $3.18 billion to $3.22 billion, representing 5.1% revenue growth as compared to fiscal 2025.”

“The Company reaffirms its full-year fiscal 2026 non-GAAP fully diluted EPS guidance to be in the range of $4.95 to $5.05, representing 24.4% to 26.9% growth over fiscal 2025 non-GAAP fully diluted EPS.”

Source: Globus Medical Q3 2026 release, Nov 5, 2026.

This is the company's own guidance as of Nov 5, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the GMED forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP net sales and diluted EPS, each as first reported in that quarter's release.

We do not hold a confirmed date for Globus Medical's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Nov 5, 2026

Globus Medical sells in two product categories. In Q3 2026 Musculoskeletal Solutions brought in $728.9 million of the $763.7 million total and Enabling Technologies $34.9 million, against $741.0 million and $28.0 million a year earlier. Worldwide net sales fell 0.7%, or 0.5% at constant currency. (Globus Medical Q3 2026 release, Nov 5, 2026)

Musculoskeletal Solutions are mainly implantable devices, biologics, instruments, spinal cord stimulation therapy and neuromonitoring services used in spine, orthopedic and neurosurgical procedures, plus trauma and hip and knee implants. Enabling Technologies are imaging, navigation and robotics systems, led by the ExcelsiusGPS robotic guidance and navigation platform. (Globus Medical Form 10-K, 2025, Feb 24, 2026)

Spinal cord stimulation from the Nevro acquisition drove the decline. Nevro products brought in $73.7 million, against $99.3 million, and the 10-Q says U.S. spinal cord stimulation sales fell $22.1 million on lower U.S. trial volumes. Excluding Nevro, base business sales rose 3.0% to $690.0 million, and U.S. spine grew 2% against what the CEO called difficult double-digit comparisons a year earlier. (Globus Medical Q3 2026 release, Nov 5, 2026; Globus Medical Form 10-Q, Q3 2026, Nov 5, 2026)

Enabling Technologies revenue grew 24%, and Globus deployed 73% more robot and navigation units than a year earlier. In the U.S., higher volumes added $8.1 million in spine implant sales, $5.5 million in trauma and $5.0 million in neuromonitoring. (Globus Medical Q3 2026 release, Nov 5, 2026; Globus Medical Form 10-Q, Q3 2026, Nov 5, 2026)

U.S. net sales rose 0.5% to $621.0 million and international net sales fell 5.7% to $142.7 million (5.0% at constant currency), with declines in Europe and the Middle East, Latin America and Asia Pacific. (Globus Medical Q3 2026 release, Nov 5, 2026; Globus Medical Form 10-Q, Q3 2026, Nov 5, 2026)

Globus Medical's GAAP diluted EPS rose 18.2% to $1.04 in Q3 2026 and non-GAAP diluted EPS rose 4.4% to $1.23. The main item between them is amortization of intangibles, $0.22 a share, plus a $0.03 litigation provision, net of a $0.06 tax effect. GAAP EPS grew faster mainly because the year-ago quarter carried a $28.3 million litigation provision, or $0.21 a share. (Globus Medical Q3 2026 release, Nov 5, 2026)

Cost of sales fell $19.6 million and operating expenses fell $25.9 million, so GAAP net income rose 18.7% to $141.2 million despite lower sales. GAAP gross margin was 66.7% and adjusted gross margin 69.5%, which the CFO called the eighth straight quarter of sequential adjusted gross margin expansion. The effective tax rate rose to 23.0% from 17.4%, because the year-ago quarter had a one-time state valuation allowance release. (Globus Medical Q3 2026 release, Nov 5, 2026; Globus Medical Form 10-Q, Q3 2026, Nov 5, 2026)

Globus repurchased 1.9 million shares for $142.9 million in the quarter, at an average of $74.61, and 3.5 million shares for $279.0 million over nine months. On November 2, 2026 its board added $500.0 million to the program, leaving about $611.0 million available. Diluted weighted average shares were 136.0 million, against 135.4 million. (Globus Medical Form 10-Q, Q3 2026, Nov 5, 2026; Globus Medical Q3 2026 release, Nov 5, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Globus Medical gives full-year guidance in its release, not quarterly guidance. In Q3 2026 it cut full-year revenue guidance to $3.09 billion from $3.18 billion to $3.22 billion, which it says is 5.1% growth over 2025, and reaffirmed non-GAAP fully diluted EPS of $4.95 to $5.05, or 24.4% to 26.9% growth. (Globus Medical Q3 2026 release, Nov 5, 2026)

Globus does not give a GAAP EPS outlook, saying it cannot predict items such as litigation provisions, amortization and acquisition-related costs. (Globus Medical Q3 2026 release, Nov 5, 2026)

A consensus figure is the average of the models published by the analysts who cover Globus Medical, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Globus Medical's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning GMED is on is GMED a buy or a sell?, what analysts expect next is on the GMED forecast, and what the company does is on the Globus Medical (GMED) stock page.

Every number on this page can be traced to a document Globus Medical published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.